alexa LATITUDE and STAMPEDE Trials Presented at ASCO 2017 offer Refreshing, Practicing-Changing Alternatives to Upfront Docetaxel for Men with High-Risk Metastatic Prostate Cancer, but Questions Remain | Open Access Journals
ISSN: 2168-9857
Medical & Surgical Urology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

LATITUDE and STAMPEDE Trials Presented at ASCO 2017 offer Refreshing, Practicing-Changing Alternatives to Upfront Docetaxel for Men with High-Risk Metastatic Prostate Cancer, but Questions Remain

Marc R Matrana*

Assistant Professor of Medicine, LSU Health Science Center School of Medicine at New Orleans, USA

*Corresponding Author:
Marc R Matrana
Assistant Professor of Medicine
LSU Health Science Center School of Medicine at New Orleans, USA
Tel: 504-842-3910
Email: [email protected]hsner.org

Received date: June 09, 2017; Accepted date: June 12, 2017; Published date: June 19, 2017

Citation: Matrana MR (2017) LATITUDE and STAMPEDE Trials Presented at ASCO 2017 offer Refreshing, Practicing-Changing Alternatives to Upfront Docetaxel for Men with High-Risk Metastatic Prostate Cancer, but Questions Remain. Med Sur Urol 6:e120. doi:10.4172/2168-9857.1000e120

Copyright: © 2017 Matrana MR. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Medical & Surgical Urology

Editorial

Among the most intriguing and practice-changing data presented at the American Society of Clinical Oncology’s (ASCO) giant annual meeting in Chicago this year were the results of the LATITUDE and STAMPEDE trials that suggest that men with high-risk hormonesensitive metastatic prostate cancer may derived the same benefit from adding upfront abiraterone with prednisone to androgen deprivation therapy (ADT) as they would from docetaxel and ADT.

Previously, the CHARTED study and earlier results of the STAMPEDE and other studies showed that adding six cycles of chemotherapy to initial ADT in this population improved outcomes, particularly improving overall survival (OS) for these at risk patients. The new data, questions whether this is actually necessary, if a less toxic, better tolerated oral hormonal therapy can be just as efficacious. Of course, no head to head comparisons have been made, but the data is stunning.

The STAMPEDE trial is the largest randomized clinical trial for prostate cancer treatments and is a multi-stage, multi-arm adaptive trial. Its abiratarone arm closed in January 2014. Data presented at ASCO showed that adding abiraterone to upfront ADT improved OS by 37%. Likewise, the LATITUDE trial randomly assigned 1,199 patients with newly diagnosed high-risk, hormone-sensitive metastatic prostate cancer to receive ADT plus placebo vs. ADT plus abiraterone and prednisone. OS survival in the control group was 34.7 months, while OS in the treatment arm was not reached (HR 0.62, 95% CI [0.51, 0.76]; p<0.0001). The OS rates at 3 years were 66% for those receiving abiraterone and 49% in the control arm.

The results imply at that a safe, well tolerated oral hormonal therapy can achieve similar or perhaps even better outcomes than chemotherapy when added to ADT in these patients. Certainly, this is good news for patients and providers, but questions remain. The trials presented were designed prior to release of the outcomes of CHAARTED and similar trials, so it is unclear if combining abiraterone, chemotherapy, and ADT may achieve an even greater benefit, or sequencing these therapies might be appropriate. Likewise, questions remain of whether this strategy would be equally beneficial to men with lower-risk hormone-sensitive metastatic prostate cancer.

Nonetheless, these intriguing results will likely mean men with lifethreatening metastatic prostate cancer will be able to achieve impressive survival advantage without the upfront use of toxic chemotherapy and that is an accomplishment all can appreciate.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 237
  • [From(publication date):
    June-2017 - Sep 24, 2017]
  • Breakdown by view type
  • HTML page views : 203
  • PDF downloads :34
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords